Clinical Trials - September 22, 2021
RhoVac completes patient recruitment for phase IIb study
RhoVac’s clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and no additional patients will be screened after this week. Top-line results of the study are estimated to be at hand in the first half of 2022, the company states. RhoVac started the clinical phase IIb trial […]
Clinical Trials - April 23, 2021
RhoVac adds prestigious hospital to its Phase IIb trial
RhoVac has announced that Mount Sinai hospital in New York is being initiated as the latest addition to US trial centres in the company’s clinical phase IIb study, “BRaVac”, in prostate cancer. The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track Designation. Immediately after the news on the […]
Pharma Business - November 25, 2020
RhoVac’s prostate cancer drug candidate granted Fast Track Designation
The American FDA has granted Fast Track Designation to the company’s drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate development of drugs aimed at treating serious or life-threatening conditions and fill unmet medical needs. The granted Fast Track Designation means that Rhovac and RV001 […]
Clinical Trials - August 11, 2020
First patient in treatment in RhoVac’s phase IIb study in the US
RhoVac announces that the first patient in the USA is included in the company’s clinical phase IIb study in prostate cancer, a study entitled RhoVac-002. The first US clinic to include a patient in the study was Carolina Urologic Research Center. An international, multi-centre study BraVac is a randomized, placebo controlled and double-blind study, with […]
